Rishi Gupta
Directeur/Membre du Conseil chez ENLIVEN THERAPEUTICS, INC.
Fortune : - $ au 30/04/2024
Profil
Rishi Gupta is currently a Director at Symbiomix Therapeutics LLC, Avitide, Inc., Turnstone Biologics, Inc., Attenua, Inc., Pionyr Immunotherapeutics, Inc., Meves Pharmaceuticals, Inc., Modis Therapeutics, Inc., Turnstone Biologics Corp., Enliven Therapeutics, Inc., Charm Therapeutics Ltd., Enliven Therapeutics, Inc., Aer Therapeutics, Inc., CHARM Therapeutics, Inc., and OrbiMed Advisors Private Equity.
He previously worked as an Independent Director at ChemoCentryx, Inc. from 2011 to 2013, a Director at Gelesis, Inc., Arsanis, Inc., NeuroPace, Inc. from 2019 to 2021, Verona Pharma Plc from 2016 to 2024, Sientra, Inc., Dimension Therapeutics, Inc., OrbiMed Private Investments VI LP, and Oric Pharmaceuticals, Inc. He also worked as a Financial Analyst at Raymond James Financial, Inc. from 1999 to 2000 and as an Associate at Wachtell, Lipton, Rosen & Katz.
Mr. Gupta holds a graduate degree from Yale Law School in 2004 and an undergraduate degree from Harvard College in 1999.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 | |
VERONA PHARMA PLC
-.--% | 28/04/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
| 08/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Rishi Gupta
| Sociétés | Poste | Début |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Directeur/Membre du Conseil | 01/10/2016 |
| ENLIVEN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 23/02/2023 |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Directeur/Membre du Conseil | - |
Aer Therapeutics, Inc.
 Aer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer. | Directeur/Membre du Conseil | - |
Charm Therapeutics Ltd.
 Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Directeur/Membre du Conseil | - |
Enliven Therapeutics, Inc. /US/
 Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
Pionyr Immunotherapeutics, Inc.
 Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
Meves Pharmaceuticals, Inc.
 Meves Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Meves Pharmaceuticals, Inc. provides pharmaceutical products and services. The company is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Attenua, Inc.
 Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Directeur/Membre du Conseil | - |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Rishi Gupta
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░ ░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Rishi Gupta
| Yale Law School | Graduate Degree |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| SIENTRA, INC. | Health Technology |
| VERONA PHARMA PLC | Health Technology |
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| NEUROPACE, INC. | Health Technology |
| RAYMOND JAMES FINANCIAL, INC. | Finance |
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 20 |
|---|---|
Raymond James & Associates, Inc.
 Raymond James & Associates, Inc. Financial ConglomeratesFinance Raymond James & Associates, Inc. (RJA) is a registered broker-dealer headquartered in St. Petersburg, Florida. The firm was founded in 1962 and is a subsidiary of Raymond James Financial, Inc. (NYSE: RJF), a diversified holding company. RJA offers a full array of capital markets services, strategic advice and planning for institutional investors. | Finance |
Wachtell, Lipton, Rosen & Katz
 Wachtell, Lipton, Rosen & Katz Miscellaneous Commercial ServicesCommercial Services Wachtell, Lipton, Rosen & Katz provides advisory and legal services. It specializes in mergers and acquisitions, strategic investments, takeovers and takeover defense, corporate and securities law, and corporate governance. The company was founded in 1965 and is headquartered in New York, NY. | Commercial Services |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Veritas Medicine, Inc.
 Veritas Medicine, Inc. Internet Software/ServicesTechnology Services Veritas Medicine, Inc. operates an online database of clinical trials. It offers patient enrollment solutions to determine eligibility for upcoming clinical trials. The company was founded by Robert Adelman, Joshua Schultz, and Stephen Knight in 1999 and is headquartered in Cambridge, MA. | Technology Services |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Symbiomix Therapeutics LLC
 Symbiomix Therapeutics LLC BiotechnologyHealth Technology Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ. | Health Technology |
Avitide, Inc.
 Avitide, Inc. BiotechnologyHealth Technology Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH. | Health Technology |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
Modis Therapeutics, Inc.
 Modis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA. | Commercial Services |
Attenua, Inc.
Attenua, Inc. Pharmaceuticals: MajorHealth Technology Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA. | Health Technology |
Meves Pharmaceuticals, Inc.
Meves Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Meves Pharmaceuticals, Inc. provides pharmaceutical products and services. The company is headquartered in New York, NY. | Health Technology |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Health Technology |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
OrbiMed Private Investments VI LP
 OrbiMed Private Investments VI LP Investment ManagersFinance Orbimed Private Investments VI LP seeks investment opportunities companies located in North America and Europe. The fund targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage, early stage, and later stage companies for both public and private companies with an investment size of $10 million to $75 million. | Finance |
Charm Therapeutics Ltd.
Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Health Technology |
Aer Therapeutics, Inc.
Aer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer. | Health Technology |
| Charm Therapeutics, Inc. |